Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

NCT01206101 on ClinicalTrials.gov · last registry update 2017-03-30

Stopped early, having planned 3 participants. The sponsor logged completion for 3 June 2013. Primary outcome, as filed: Proportion Of Insulin-independent Subjects After Receiving Only One (Single-Donor) Islet Cell Transplant. liraglutide is approved in the US, but not for diabetes and type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: TERMINATED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 3
Started: 2012-03-21
Primary completion: 2013-06-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Proportion Of Insulin-independent Subjects After Receiving Only One (Single-Donor) Islet Cell Transplant

Conditions studied

Diabetes · Diabetes Mellitus, Type 1

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.